Literature DB >> 26178300

PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.

Stephan Macher-Goeppinger1,2, Martina Keith1,2, Katrin E Tagscherer1,2, Stephan Singer1, Juliane Winkler1, Thomas G Hofmann3, Sascha Pahernik4, Stefan Duensing5, Markus Hohenfellner4, Juergen Kopitz6, Peter Schirmacher1, Wilfried Roth1,2.   

Abstract

About 40% of clear-cell renal cell carcinomas (ccRCC) harbour mutations in Polybromo-1 (PBRM1), encoding the BAF180 subunit of a SWI/SNF chromatin remodelling complex. This qualifies PBRM1 as a major cancer gene in ccRCC. The PBRM1 protein alters chromatin structure and its known functions include transcriptional regulation by controlling the accessibility of DNA and influencing p53 transcriptional activity. Since little is known about the regulation of PBRM1, we studied possible mechanisms and interaction partners involved in the regulation of PBRM1 expression. Activation of p53 in RCC cells resulted in a marked decrease of PBRM1 protein levels. This effect was abolished by siRNA-mediated down-regulation of p53, and transcriptional activity was not crucial for p53-dependent PBRM1 regulation. Pulse-chase experiments determined post-translational protein degradation to be the underlying mechanism for p53-dependent PBRM1 regulation, which was accordingly inhibited by proteasome inhibitors. The effects of p53 activation on PBRM1 expression were confirmed in RCC tissue ex vivo. Our results demonstrate that PBRM1 is a target of p53-induced proteasomal protein degradation and provide further evidence for the influence of PBRM1 on p53 function in RCC tumour cells. Considering the paramount role of p53 in carcinogenesis and the presumptive impact of PBRM1 in RCC development, this novel regulation mechanism might be therapeutically exploited in the future.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  PBRM1; TP53; kidney; protein degradation; renal cell carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26178300     DOI: 10.1002/path.4592

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing.

Authors:  Emma J Chory; Jacob G Kirkland; Chiung-Ying Chang; Vincent D D'Andrea; Sai Gourisankar; Emily C Dykhuizen; Gerald R Crabtree
Journal:  ACS Chem Biol       Date:  2020-05-27       Impact factor: 5.100

Review 2.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 3.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

4.  Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma.

Authors:  A Murakami; L Wang; S Kalhorn; P Schraml; W K Rathmell; A C Tan; R Nemenoff; K Stenmark; B-H Jiang; M E Reyland; L Heasley; C-J Hu
Journal:  Oncogenesis       Date:  2017-01-16       Impact factor: 7.485

Review 5.  Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.

Authors:  Ali Mehdi; Yasser Riazalhosseini
Journal:  Int J Mol Sci       Date:  2017-08-16       Impact factor: 5.923

6.  p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics.

Authors:  Karoline Diesing; Silvia Ribback; Stefan Winter; Christopher H Lillig; Nils Kroeger; Manuela Gellert; Antonia M Oster; Viktoria Stühler; Eva Gläser; Frank Adler; Christoph Hartwig; Markus Scharpf; Jens Bedke; Martin Burchardt; Matthias Schwab
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-09       Impact factor: 4.553

7.  A Gene Module-Based eQTL Analysis Prioritizing Disease Genes and Pathways in Kidney Cancer.

Authors:  Mary Qu Yang; Dan Li; William Yang; Yifan Zhang; Jun Liu; Weida Tong
Journal:  Comput Struct Biotechnol J       Date:  2017-10-10       Impact factor: 7.271

8.  Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.

Authors:  Vassilios Myrianthopoulos; Nicolas Gaboriaud-Kolar; Cynthia Tallant; Michelle-Lynn Hall; Stylianos Grigoriou; Peter Moore Brownlee; Oleg Fedorov; Catherine Rogers; David Heidenreich; Marek Wanior; Nikolaos Drosos; Nikitia Mexia; Pavel Savitsky; Tina Bagratuni; Efstathios Kastritis; Evangelos Terpos; Panagis Filippakopoulos; Susanne Müller; Alexios-Leandros Skaltsounis; Jessica Ann Downs; Stefan Knapp; Emmanuel Mikros
Journal:  J Med Chem       Date:  2016-09-27       Impact factor: 7.446

9.  Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.

Authors:  Svenja Bihr; Riuko Ohashi; Ariane L Moore; Jan H Rüschoff; Christian Beisel; Thomas Hermanns; Axel Mischo; Claudia Corrò; Jörg Beyer; Niko Beerenwinkel; Holger Moch; Peter Schraml
Journal:  Neoplasia       Date:  2019-01-16       Impact factor: 5.715

Review 10.  Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma.

Authors:  Lucía Carril-Ajuria; María Santos; Juan María Roldán-Romero; Cristina Rodriguez-Antona; Guillermo de Velasco
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.